National Comprehensive Cancer Network

Members Only
NCCN Oncology Research Program (ORP)
NCCN Volasertib Research Grant Opportunity – Submit by October 30, 2014
NCCN ORP Recent News
NCCN ORP Affiliate Research Consortium
NCCN ORP Scientific Publications
NCCN ORP for Industry
NCCN ORP Investigator Steering Committee
NCCN ORP Testimonials
NCCN Clinical Trials at NCCN Member Institutions
Find NCCN ORP Funded Clinical Trials at NCCN Member Institutions
NCCN Informed Consent Language Database
NCCN Specialized Imaging Research Consortium™ (SIRC)
NCCN ORP Disclosure Policy
NCCN Collaboration with the National Business Group on Health
NCCN Health Information Technology Licensees

NCCN Research & Business Resources

NCCN ORP Scientific Publications


Bibliography: NCCN Oncology Research Program Manuscripts

Bibliography: NCCN Oncology Research Program Abstracts



NCCN ORP Manuscripts


Brain Cancer

Chamberlain MC & Johnston, SK. Salvage therapy with single agent bendamustine for recurrent glioblastoma. J Neuro-Oncol 2011;105:523–30.
http://www.ncbi.nlm.nih.gov/pubmed/21626071


Breast Cancer

Layman RM, Ruppert AS, Lynn M, et al. Severe and prolonged lymphopenia observed in patients treated with bendamustine and erlotinib for metastatic triple negative breast cancer. Cancer Chemother Pharmacol in press 2013;71:1183–1190.
http://link.springer.com/article/10.1007%2Fs00280-013-2112-2#

Reinbolt RE, Alam S, Layman R, et al. Pneumocystis jiroveci pneumonia in an atypical host.  Clin Breast Cancer 2012;12:138–141.
http://www.ncbi.nlm.nih.gov/pubmed/22133356

Lustberg MB, Povoski SP, Zhao W, et al. Phase II trial of neoadjuvant exemestane in combination with celecoxib in postmenopausal women who have breast cancer. Clin Breast Cancer 2011;11:221–227.
http://www.ncbi.nlm.nih.gov/pubmed/21729671

Moulder S, Valkov N, Neuger A, et al. Phase 2 study of gemcitabine and irinotecan in metastatic breast cancer with correlatives to determine topoisomerase I localization as a predictor of response. Cancer 2008;113:2646–2654.
http://onlinelibrary.wiley.com/doi/10.1002/cncr.23916/pdf

Mrozek E, Kolesar J, Young D, et al. Phase II study of sequentially administered low–dose mitomycin–C (MMC) and irinotecan (CPT–11) in women with metastatic breast cancer. Ann Oncol 2008;19:1417–1422.
http://annonc.oxfordjournals.org/content/early/2008/04/11/annonc.mdn154.full

O’Connor T, Rustum Y, Levine E & Creaven P. A phase I study of capecitabine and a modulatory dose of irinotecan in metastatic breast cancer. Cancer Chemother Pharmacol 2008;61:125–131.
http://www.springerlink.com/content/kw601j77145t6023/


Gastrointestinal Cancer

Uronis HE, Bendell JC, Altomare I, et al. A phase II study of capecitabine, oxaliplatin, and bevacizumab in the treatment of metastatic esophagogastric adenocarcinomas. Oncologist 2013;18:271–272.
http://www.ncbi.nlm.nih.gov/pubmed/23485624

Ko AH, Espinoza AM, Jones KA, et al. Optimizing the administration of fixed–dose rate gemcitabine plus capecitabine using an alternating–week schedule: a dose finding and early efficacy study in advanced pancreatic and biliary carcinomas. Am J Clin Oncol 2012;35:411–417.
http://www.ncbi.nlm.nih.gov/pubmed/21552099?log$=activity

Zhang X, Louie A, Li X, et al. A Simple and sensitive LC–MS/MS method for simultaneous determination of temsirolimus and its major metabolite in human whole blood. Chromatographia 2012;75:1405–1413.
http://link.springer.com/content/pdf/10.1007%2Fs10337–012–2341–2

Hill ME, Li X, Kim S, et al. A phase I study of the biomodulation of capecitabine by docetaxel and gemcitabine (mGTX) in previously untreated patients with metastatic adenocarcinoma of the pancreas. Cancer Chemother Pharmacol 2011;67:511–517.
http://www.springerlink.com/content/t241853g000514jv/

Weekes CD, Nallapareddy S, Rudek MA, et al. Thymidylate synthase (TYMS) enhancer region genotype–directed phase II trial of oral capecitabine for 2nd line treatment of advanced pancreatic cancer.  Invest New Drugs 2011;29:1057–1065.
http://www.springerlink.com/content/e13354576r8j1676/

Saif MW, Lansigan F, Ruta S, et al. Phase I study of the botanical formulation PHY906 with capecitabine in advanced pancreatic and other gastrointestinal malignancies. Phytomedicine 2010;17:161–169.
http://www.ncbi.nlm.nih.gov/pubmed/20092990?itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum&ordinalpos=3

Burkitt K, Chun SY, Dang DT, & Dang LH. Targeting both HIF–1 and HIF–2 in human colon cancer cells improves tumor response to sunitinib treatment. Mol Cancer Ther 2009;8:1148–1156.
http://mct.aacrjournals.org/content/8/5/1148.long

George S, Merriam P, Maki GR, et al. Multicenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas. J Clin Oncol 2009;27:3154–3160.
http://jco.ascopubs.org/cgi/content/abstract/27/19/3154

Javle M, Yu J, Garrett C, et al. Bevacizumab combined with gemcitabine and capecitabine for advanced pancreatic cancer: a phase II study. Br J Cancer 2009;100:1842–1845.
http://www.nature.com/bjc/journal/v100/n12/abs/6605099a.html

Jimeno A, Amador ML, Kulesza P, et al. Assessment of celecoxib pharmacodynamics in pancreatic cancer. Mol Cancer Ther 2006;5:3240–3247.
http://mct.aacrjournals.org/content/5/12/3240.full


General

He L, Grecula JC, Ling Y, et al. Development and validation of sensitive liquid chromatography/tandem mass spectrometry method for quantification of bendamustine in mouse brain tissue. J Chromatogr B 2012;905:141–144.
http://dx.doi.org/10.1016/j.jchromb.2012.08.013

Milind MJ, Cao S, Durrani AF, et al. Celecoxib and mucosal protection: Translation from an animal model to a phase I clinical trial of Celecoxib, Irinotecan, and 5-Fluorouracil. Clin Cancer Res 2007;13:965–971.
http://clincancerres.aacrjournals.org/content/13/3/965.full


Head and Neck Cancer

Fury MG, Sherman E, Ho A, et al. A phase I study of temsirolimus plus carboplatin plus paclitaxel for patients with recurrent or metastatic (R/M) head and neck squamous cell cancer (HNSCC). Cancer Chemother Pharmacol 2012;70:121–128.
http://www.ncbi.nlm.nih.gov/pubmed/22644799

Fury MG, Sherman E, Lisa D, et al. A randomized phase II study of cetuximab every 2 weeks at either 500 or 750 mg/m2 for patients with recurrent or metastatic head and neck squamous cell cancer. JNCCN 2012;10:1391–1398.
http://www.ncbi.nlm.nih.gov/pubmed/23138167

Fury MG, Sherman EJ, Rao SS, et al. Phase I Study of weekly nab-paclitaxel + weekly cetuximab + intensity-modulated radiation therapy (IMRT) in patients with stage III-IVB head and neck squamous cell carcinoma (HNSCC) Ann Oncol 2014 Mar;25(3):689-94. doi: 10.1093/annonc/mdt579. Epub 2014 Feb 3
http://www.ncbi.nlm.nih.gov/pubmed/24496920

Ho, AL, Lipson BL, Sherman EJ et al. A Phase II Study of Pralatrexate with Vitamin B12 and Folic Acid Supplementation for Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Cancer. Investigational New Drugs: February 25, 2014.
http://link.springer.com/article/10.1007/s10637-014-0073-x


Hepatocellular Carcinoma

Kelley RK, Nimeiri HS, Munster PN, et al. Temsirolimus combined with sorafenib in hepatocellular carcinoma: a phase I dose-finding trial with pharmacokinetic and biomarker correlates. Ann Oncol 2013;00:1–8.
http://annonc.oxfordjournals.org/content/early/2013/03/20/annonc.mdt109.abstract

Fu S, Naing A, Moulder SL, et al. Phase I trial of hepatic arterial infusion of nanoparticle albumin–bound paclitaxel: toxicity, pharmacokinetics, and activity. Mol Cancer Ther 2011;10:1300–1307.
http://www.ncbi.nlm.nih.gov/pubmed/21571911


Lung Cancer

Komaki R, Wei X, Allen PK, et al. Phase I study of celecoxib with concurrent irinotecan, cisplatin, and radiation therapy for patients with unresectable locally advanced non-small cell lung cancer. Front. Oncol 2011;1:52.
http://www.frontiersin.org/Thoracic_Oncology/10.3389/fonc.2011.00052/abstract

Shao H, Tang H, Salavaggione OE, et al. Improved response to nab–paclitaxel compared with cremophor–solubilized paclitaxel is independent of secreted protein acidic and rich in cysteine expression in non–small cell lung cancer. J Thorac Oncol 2011;6:998–1005.
http://www.ncbi.nlm.nih.gov/pubmed/21532503


Prostate Cancer

Armstrong AJ, Shen T, Halabi S, et al. A phase II trial of Temsirolimus in men with castration-resistant metastatic prostate cancer. Clin Genitourin Cancer 2013;13:138–139.
http://www.ncbi.nlm.nih.gov/pubmed/23830964


Renal Cell Cancer

Bhatt RS, Wang X, et al. Renal cancer resistance to antiangiogenic therapy is delayed by restoration of angiostatic signaling. Mol Cancer Ther 2010;9:2793–2802.
http://mct.aacrjournals.org/content/9/10/2793.abstract

Rini BI, Weinberg V, Dunlap S, et al. Maximal COX-2 immunostaining and clinical response to celecoxib and interferon alpha therapy in metastatic renal cell carcinoma. Cancer 2006;106:566–575.
http://onlinelibrary.wiley.com/doi/10.1002/cncr.21661/full


Sarcoma

Thornton KA, Cheri AR, Trucco MM, et al. A dose-finding study of temsirolimus and liposomal doxorubicin for patients with recurrent and refractory bone and soft tissue sarcoma. Int J Cancer 2013;133:997–1005. http://www.ncbi.nlm.nih.gov/pubmed/23382028

Yoon SS, Stangenberg L, Jin-Lee Y, et al. Efficacy of Sunitinib and radiotherapy in genetically engineered mouse model of soft-tissue sarcoma. Int J Radiat Oncol Biol Phys 2009;74:1207–1216.
http://www.sciencedirect.com/science/article/pii/S0360301609003502


Solid Tumors

Tsimberidou AM, Adamopoulos AM, Ye Y et al. Phase I Clinical Trial of Bendamustine and Bevacizumab for Patients with Advanced Cancer. J Natl Compr Canc Netw. 2014 Feb 1;12(2):194-203.
http://www.ncbi.nlm.nih.gov/pubmed/24586081

Twardowski PW, Smith-Powell L, Carroll M, et al. Biologic markers of angiogenesis: Circulating endothelial cells in patients with advanced malignancies treated on phase I protocol with metronomic chemotherapy and celecoxib. Cancer Invest 2008;26:53–59.
http://informahealthcare.com/doi/abs/10.1080/07357900701681541

Saif WM, Sellers S, Li M, et al. A phase I study of bi–weekly administration of 24­–h gemcitabine followed by 24–h irinotecan in patients with solid tumors. Cancer Chemother Pharmacol 2007;60:871–882.
http://link.springer.com/article/10.1007%2Fs00280–007–0434–7


Thyroid Cancer

Mrozek E, Kloos TR, Ringel DM, et al. Phase II study of celecoxib in metastatic differentiated thyroid carcinoma. J Clin Endocrinology & Metabolism 2006;91:2201–2204.
http://jcem.endojournals.org/content/91/6/2201.full



NCCN ORP Abstracts


Brain Cancer

Johnston SK & Chamberlain MC.  Salvage therapy with single agent bendamustine for recurrent anaplastic glioma [abstract].  J Clin Oncol 2011;29:Abstract 12506.
http://meeting.ascopubs.org/gca?allch=&submit=Go&gca=ascomtg%3B29%2F15_suppl%2Fe12506

Johnston SK, Graham C, Grimm S, et al.  Salvage therapy with single agent bendamustine for recurrent glioblastoma [abstract].  J Neuro-Oncol 2011;105:Abstract OT-04. 
http://connection.ebscohost.com/c/articles/67187338/salvage-therapy-single-agent-bendamustine-recurrent-glioblastoma

Chamberlain MC, Graham C, Mrugala M & Johnston S.  Bendamustine for recurrent glioblastoma [abstract].  Society Neuro-Oncol  2010;12(Suppl 4):Abstract OT-11. 
http://neuro-oncology.oxfordjournals.org/content/12/suppl_4/iv69.abstract

Grecula JC, Ammirati M, Kendra KL, et al.  Phase I study of bendamustine and fractionated stereotactic radiotherapy (FSRT) in patients with one to three brain metastases from solid malignancies [abstract].  J Clin Oncol 2010;28(Suppl 15):Abstract TPS146.
http://meeting.ascopubs.org/gca?allch=&submit=Go&gca=ascomtg%3B28%2F15_suppl%2FTPS146


Breast Cancer

Snider JS, Sachdev, JC, Allen, JW, et al. Pathologic complete response (pCR) with weekly nanoparticle albumin bound (nab-P) plus carboplatin (C) followed by doxorubicin plus cyclophosphamide (AC) with concurrent bevacizumab (B) for triple-negative breast cancer (TNBC). J Clin Oncol 2013;31Abstract 1068.
http://meetinglibrary.asco.org/content/117576-132

Sachdev JC, Snider J, Schwartzberg L, et al. Interim results for neoadjuvant bevacizumab with weekly nanoparticle albumin bound (nab)-paclitaxel plus carboplatin followed by doxorubicin plus cyclophosphamide (AC) in triple-negative breast cancer. J Natl Compr Canc Netw 2013;11:Abstract 2013–2.
http://www.jnccn.org/content/11/3/240.full

Snider JN, Allen JW, Young R, et al.  Neoadjuvant bevacizumab with weekly nanoparticle albumin bound (nab)-paclitaxel plus carboplatin followed by doxorubicin plus cyclophosphamide (AC) for triple negative breast cancer [abstract].  Cancer Res 2012;72(Suppl 3)Abstract OT3-3-07.
http://cancerres.aacrjournals.org/cgi/content/short/72/24_MeetingAbstracts/OT3-3-07?rss=1

Gajria D, King TA, Pannu H, et al.  Combined inhibition of mTORC1 with temsirolimus and HER2 with neratinib: A phase I study in patients with metastatic HER2-amplified breast cancer [abstract].  J Clin Oncol 2011;29:Abstract 574.
http://meeting.ascopubs.org/gca?allch=&submit=Go&gca=ascomtg%3B29%2F15_suppl%2F574

Specht JM, Kurlan BF, Dunnwald LK, et al. Dynamic FDG PET and DCE-MRI to assess tumor metabolism and blood flow in response to neoadjuvant sunitinib and paclitaxel followed by AC + G-CSF in patients with locally advanced (LABC) and/or inflammatory breast cancer (IBC) [abstract].  Cancer Res 2011;71(Suppl 3):Abstract P2-09-09.
http://cancerres.aacrjournals.org/cgi/content/meeting_abstract/71/24_MeetingAbstracts/P2-09-09

Layman RM, Ruppert AS, Lynn M, et al.  Severe and prolonged lymphopenia observed In patients treated with bendamustine and erlotinib for metastatic triple negative breast cancer [abstract].  ASH Annual Meeting Abstracts 2010;116:Abstract 1739. https://ash.confex.com/ash/2010/webprogram/Paper33701.html

Sachdev JC, Kronish LE, West S, et al.  Neoadjuvant bevacizumab with weekly nanoparticle albumin bound nab-paclitaxel plus carboplatin followed by doxorubicin plus cyclophosphamide (AC) for triple-negative breast cancer [abstract].  J Clin Oncol 2010;28(Suppl 15):Abstract TPS100.
http://meeting.ascopubs.org/gca?allch=&submit=Go&gca=ascomtg%3B28%2F15_suppl%2FTPS100

Specht JM, Partridge S, Dunnwald L, et al.  DCE-MRI and dynamic FDG PET to monitor breast cancer response to neoadjuvant sunitinib in patients with locally-advanced breast cancer [abstract].  Cancer Res 2009;69(Suppl 1):Abstract 6006.
http://hwmaint.cancerres.aacrjournals.org/cgi/content/meeting_abstract/69/2_MeetingAbstracts/6006

Shapiro CL, Povoski SP, Jiminez R, et al.  Phase II trial of neoadjuvant exemestane [EXE] and celecoxib [CELE] in breast cancer: Results of biomarkers [abstract].  J Clin Oncol 2007;25(Suppl 18):Abstract 11056.
http://meeting.ascopubs.org/gca?allch=citmgr&gca=ascomtg%3B25%2F18_suppl%2F11056&submit=Go

Moulder SL, Valkov N, Minton S, et al.  A single arm phase II trial of gemcitabine (G) and irinotecan (I) in metastatic breast cancer (MBC): can localization of topoisomerase I (topo I) predict response to topo I inhibitors?  J Clin Oncol 2006;24(Suppl 18):Abstract 661.
http://meeting.ascopubs.org/gca?allch=&submit=Go&gca=ascomtg%3B24%2F18_suppl%2F661

Moulder SL, Valkov N, Gump J, et al.  Is cytoplasmic localization of topoisomerase I (topo I) a mechanism of resistance for topo I inhibitors? Results from an NCCN sponsored phase II trial of gemcitabine and irinotecan in metastatic breast cancer.  AACR Meeting Abstracts 2006:Abstract 1270-d-1271.
http://www.aacrmeetingabstracts.org/cgi/content/abstract/2006/1/1270-d

Twardowski PW, Smith-Powell L, Carrol M, et al.  Biologic markers of angiogenesis: circulating endothelial cells in patients with advanced malignancies treated on phase I protocol with metronomic chemotherapy and celecoxib [abstract].  AACR Meeting Abstracts 2006:412-b.
http://www.aacrmeetingabstracts.org/cgi/content/abstract/2006/1/412-b

Mrozek E, Kolesar J, Allen D, et al.  Phase II study of sequentially administered mitomycin (MMC) and irinotecan (CPT-11) in patients (pts) with metastatic breast cancer (MBC).  J Clin Oncol 2006;24(Suppl 18):Abstract 10542.
http://meeting.ascopubs.org/gca?allch=&submit=Go&gca=ascomtg%3B24%2F18_suppl%2F10542

Moulder SL, Munster P, Minton S, et al.  Results of a planned efficacy and safety analysis for a National Comprehensive Cancer Network sponsored phase II study of gemcitabine and irinotecan (GI) in metastatic breast cancer (MBC).  J Clin Oncol 2005;23(Suppl 16):Abstract 679.
http://meeting.ascopubs.org/gca?allch=&submit=Go&gca=ascomtg%3B23%2F16_suppl%2F679


Gastrointestinal Cancer

Kelley RK, Chang AN, Anguiano E et al. Next-generation sequencing (NGS) of serum microRNA in hepatocellular carcinoma (HCC) patients treated with sorafenib and an mTOR inhibitor. J Clin Oncol 32 2014 (suppl 3; abstr LBA204).
http://meetinglibrary.asco.org/content/123022-143

Chan E, Arlinghaus LR, Cardin DB, et al.  Phase I trial of chemoradiation with capecitabine and vorinostat in pancreatic cancer [abstract].  J Clin Oncol 2013;30(Suppl 34):Abstract 225.
http://meeting.ascopubs.org/gca?allch=&submit=Go&gca=ascomtg%3B31%2F4_suppl%2F225

Malhotra U, Miller A, Adjei A, et al. Pralatrexate (P) plus oxaliplatin (O) in advanced esophagogastric cancer: preliminary report of the safety lead-in cohort in a phase II trial. J Natl Compr Canc Netw 2013;11:Abstract 2013–15.
http://www.jnccn.org/content/11/4/373.full

Espinoza AM, Ko AH, Venook AP, et al.  A phase I study, with expanded cohort, of biweekly fixed-dose rate gemcitabine (FDR GEM) plus capecitabine (CAP) in patients with advanced pancreatic (APC) and biliary carcinomas (ABC) [abstract].  J Clin Oncol 2010;28(Suppl 15):Abstract 4136.
http://meeting.ascopubs.org/gca?allch=&submit=Go&gca=ascomtg%3B28%2F15_suppl%2F4136

Saif M, Li J, Lamb L, et al.  Phase II study of PHY906 plus capecitabine (CAP) in pts with gemcitabine-refractory pancreatic cancer (PC) and measurement of cytokines [abstract].  J Clin Oncol 2010;28:Abstract e14540.
http://meeting.ascopubs.org/gca?allch=&submit=Go&gca=ascomtg%3B28%2F15_suppl%2Fe14540

Weekes C, Nallapareddy S, Jimeno A, et al.  Single nucleotide polymorphisms of TSER, ATM, RecQ1 genes association with survival in pancrease cancer [abstract].  J Clin Oncol 2009;27:Abstract e14590.
http://meeting.ascopubs.org/gca?allch=&submit=Go&gca=ascomtg%3B27%2F15S%2Fe14590

Burkitt K, Chun S, Dang D, et al.   Sunitinib therapy is additive/synergistic with blockade of HIF-1 and -2 in colon cancer cells [abstract].  AACR Meeting Abstracts 2008:Abstract 4042.
http://www.aacrmeetingabstracts.org/cgi/content/meeting_abstract/2008/1_Annual_Meeting/4042?maxtoshow=&hits=10&RESULTFORMAT=&author1=dang&fulltext=Sunitinib+&andorexactfulltext=and&searchid=1&FIRSTINDEX=0&sortspec=relevance&resourcetype=HWCIT


General

Hammers H, Paesante S, Shen L, et al.  Combination of the VEGF receptor tyrosine kinase sunitinib and the mTOR inhibitor rapamycin leads to tumor regression in the RENCA model [abstract].  AACR Meeting Abstracts 2008:Abstract 1104.
http://www.aacrmeetingabstracts.org/cgi/content/meeting_abstract/2008/1_Annual_Meeting/1104?maxtoshow=&hits=10&RESULTFORMAT=&author1=hammers&andorexactfulltext=and&searchid=1&FIRSTINDEX=0&sortspec=relevance&resourcetype=HWCIT


Genitourinary Cancer

Alva AS, Argarwal N, Siefker-Radtke AO, et al.  Targeting epidermal growth factor receptor (EGFR) in urothelial cancer (UC): A phase II randomized trial of cisplatin (C) with gemcitabine (G) with or without cetuximab [abstract].  J Clin Oncol 2010;28(Suppl 15):Abstract TPS239. 
http://meeting.ascopubs.org/gca?allch=&submit=Go&gca=ascomtg%3B28%2F15_suppl%2FTPS239


Head and Neck Cancer

Teknos TN, Old M, Ozer E, et al. A phase I trial of vorinostat in combination with standard chemoradiation therapy in advanced oropharyngeal squamous cell carcinoma: preliminary results. J Natl Compr Canc Netw 2013;11:Abstract 2013–14.
http://www.jnccn.org/content/11/4/373.full

Fury MG, Sherman EJ, Rao SS, et al. Phase I study of weekly albumin-bound paclitaxel (ab-P) plus weekly cetuximab (Cet) plus intensity-modulated radiation therapy (IMRT) in patients with stage III/IVb head and neck squamous cell carcinoma (HNSCC). J Clin Oncol 2013;31:Abstract 6034.
http://meetinglibrary.asco.org/content/110307-132

Khushalani NI, Yang G, Tan W, et al.  Gene expression profile (GEP) for the prediction of pathologic complete response (pCR): Preliminary data from a neoadjuvant study of capecitabine (C), oxaliplatin (OXP), and radiation (RT) for esophageal cancer (EC).  J Clin Oncol 2010;28(Suppl 15):Abstract 4100.
http://meeting.ascopubs.org/gca?allch=&submit=Go&gca=ascomtg%3B28%2F15_suppl%2F4100


Hepatocellular Carcinoma

Kelley RK, Nimeiri HS, Munster PN, et al.  Phase I trial of temsirolimus (TEM) plus sorafenib (SOR) in advanced hepatocellular carcinoma (HCC) with pharmacokinetic (PK) and biomarker correlates [abstract].  J Clin Oncol 2012;30:Abstract 4102. 
http://meeting.ascopubs.org/gca?allch=&submit=Go&gca=ascomtg%3B30%2F15_suppl%2F4102

Kelley RK, Nimeiri HS, Vergo, MT, et al.  Phase I trial of temsirolimus (TEM) plus sorafenib (SOR) in advanced hepatocellular carcinoma (HCC) [abstract].  J Clin Oncol 2011;29(Suppl 4):Abstract 296. 
http://meeting.ascopubs.org/gca?allch=&submit=Go&gca=ascomtg%3B29%2F4_suppl%2F296

Fu S, Naing A, Moulder SL, et al.  A phase I study of hepatic arterial infusion of nab-paclitaxel in patients with predominant hepatic metastases [abstract].  J Clin Oncol 2010;28:Abstract e13044.
http://meeting.ascopubs.org/gca?allch=&submit=Go&gca=ascomtg%3B28%2F15_suppl%2Fe13044

Kelley RK, Nimeiri HS, Vergo MT, et al.  A phase I trial of the combination of temsirolimus (TEM) and sorafenib (SOR) in advanced hepatocellular carcinoma (HCC) [abstract].  J Clin Oncol 2010;28(Suppl 15):Abstract TPS213.
http://meeting.ascopubs.org/gca?allch=&submit=Go&gca=ascomtg%3B28%2F15_suppl%2FTPS213


Lung Cancer

Mehra R, Turaka A, Meyer J, et al.  Phase I study of vorinostat with concurrent chemoradiotherapy (CRT) for locally advanced nonsquamous non-small cell lung cancer (NSCLC).  J Natl Compr Canc Netw 2013;11:Abstract 2013–1.
http://www.jnccn.org/content/11/3/240.extract

Bertino EM, Villalona-Calero MA, Nana-Sinkam P, et al.  Phase 2 Trial of nab-paclitaxel plus carboplatin for advanced NSCLC in patients at risk of bleeding from VEGF directed therapies [abstract].  Cancer Res 2012;72(Suppl 1):Abstract LB-225.  http://cancerres.aacrjournals.org/cgi/content/short/72/8_MeetingAbstracts/LB-225?rss=1

Bertino EM, Otterson GA, Villalona-Calero MA, et al.  Phase II trial of nab-paclitaxel plus carboplatin for advanced NSCLC in patients at risk of bleeding from VEGF-directed therapies [abstract].  J Clin Oncol 2010;28(Suppl 15):Abstract TPS291.
http://meeting.ascopubs.org/gca?allch=&submit=Go&gca=ascomtg%3B28%2F15_suppl%2FTPS291


Prostate Cancer

Armstrong A, Shen T, Halabi S, et al.  Phase 2 trial of temsirolimus in men with castration-resistant metastatic prostate cancer [abstract].  J Clin Oncol 2013;31(Suppl 6):Abstract 105.
http://meetinglibrary.asco.org/content/106159-134

Zollinger L, Morton K, Agarwal N, et al. 18F-FDG and FLT PET for early prediction of response to sunitinib in metastatic renal cell carcinoma. J Nucl Med 2013;54(Suppl 2):Abstract 1605.
http://jnumedmtg.snmjournals.org/cgi/content/meeting_abstract/54/2_MeetingAbstracts/1605

Armstrong AJ, Kemeny G, Turnbull JD, et al. Impact of temsirolimus and anti-androgen therapy on circulating tumor cell (CTC) biology in men with castration-resistant metastatic prostate cancer (CRPC): A phase II study. J Clin Oncol 2010;28(Suppl 15):Abstract TPS249.
http://meetinglibrary.asco.org/content/47821-74


Renal Cell Cancer

Bhatt R, Wang X, Zhang L, et al.  Cox-2 inhibition delays resistance to sunitinib in RCC xenograft models [abstract].  AACR Meeting Abstracts 2009:Abstract 153.
http://www.aacrmeetingabstracts.org/cgi/content/meeting_abstract/2009/2_Annual_Meeting/153?maxtoshow=&hits=10&RESULTFORMAT=&author1=mier&fulltext=Sunitinib+&andorexactfulltext=and&searchid=1&FIRSTINDEX=0&sortspec=relevance&resourcetype=HWCIT

Bhatt R, Zhang L, Schor-Bardach R, et al.  Effects of sorafenib administration on the IFN signaling pathway and on the expression of IFN-inducible genes in RCC tumor cells [abstract].  AACR Meeting Abstracts 2008:Abstract 1128.
http://www.aacrmeetingabstracts.org/cgi/content/meeting_abstract/2008/1_Annual_Meeting/1128?maxtoshow=&hits=10&RESULTFORMAT=&author1=mier&fulltext=Sunitinib+&andorexactfulltext=and&searchid=1&FIRSTINDEX=0&sortspec=relevance&resourcetype=HWCIT

Kumar M, Panka D, Bhatt R, et al.  Mechanism of acquired resistance to sunitinib in RCC [abstract].  AACR Meeting Abstracts 2008:Abstract 1127.
http://www.aacrmeetingabstracts.org/cgi/content/meeting_abstract/2008/1_Annual_Meeting/1127?maxtoshow=&hits=10&RESULTFORMAT=&author1=mier&fulltext=Sunitinib+&andorexactfulltext=and&searchid=1&FIRSTINDEX=0&sortspec=relevance&resourcetype=HWCIT

Yoon JL, Stangenberg L, Rothrock C, et al.  Efficacy of sunitinib with and without radiation therapy in a genetically engineered mouse model of sarcoma [abstract].  AACR Meeting Abstracts 2008:Abstract 1319.
http://www.aacrmeetingabstracts.org/cgi/content/meeting_abstract/2008/1_Annual_Meeting/1319?maxtoshow=&hits=10&RESULTFORMAT=1&author1=yoon&andorexacttitle=and&titleabstract=sunitinib+&andorexacttitleabs=and&searchid=1&FIRSTINDEX=0&sortspec=relevance&fdate=1/1/2004&tdate=12/31/2010&resourcetype=HWCIT


Sarcoma

Loeb DM, DeLorenzo KA, Chen ARS, et al.  A dose-finding study of temsirolimus and liposomal doxorubicin for patients with advanced soft tissue or bone sarcoma [abstract].  J Clin Oncol 2011;29:Abstract 10026. 
http://meeting.ascopubs.org/gca?allch=&submit=Go&gca=ascomtg%3B29%2F15_suppl%2F10026


Solid Tumor

Saif MW, Sellers S, Li M, et al.  A Phase I study of bi-weekly administration of 24-hr Gemcitabine (GEM) followed by 24-hr Irinotecan (CPT-11) in patients with solid tumors.  J Clin Oncol 2005;23(Suppl 16):Abstract 2102. 
http://meeting.ascopubs.org/gca?allch=&submit=Go&gca=ascomtg%3B23%2F16_suppl%2F2102


Thyroid Cancer

Sherman EJ, Ho A, Fury MG, et al.  A phase II study of temsirolimus/sorafenib in patients with radioactive iodine (RAI)-refractory thyroid carcinoma [abstract].  J Clin Oncol 2012;30:Abstract 5514. 
http://meeting.ascopubs.org/gca?allch=&submit=Go&gca=ascomtg%3B30%2F15_suppl%2F5514